 Can-Fite BioPharma Ltd. NYSE American: CANF TASE:CFBI, a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory and liver diseases, today announced that its Phase II exploratory NAFLDNASH study with Namodenoson achieved its efficacy endpoints, while continuing to demonstrate a good safety profile. 